This bill amends section 351(k) of the Public Health Service Act to treat a biological product licensed as a biosimilar as interchangeable with its reference product in most cases. It creates a 60‑day transition window after enactment; after that date biosimilars licensed on or after the transition are automatically deemed interchangeable upon licensure, and biosimilars licensed earlier are deemed interchangeable on the transition date—subject only to a narrow exception tied to pre‑existing ‘first interchangeable’ exclusivity.
The statute also preserves any unexpired exclusivity periods for interchangeable biologics licensed before enactment, removes cross‑references to an interchangeable determination elsewhere in the code, adjusts how pediatric “new active ingredient” questions are treated, and requires FDA to update or revoke existing interchangeability guidances within set timelines.
Why this matters: the bill eliminates the FDA’s separate pathway-based hurdle for interchangeability and replaces it with automatic legal interchangeability in many situations. That changes who can be automatically substituted at the pharmacy level, accelerates market entry for biosimilars that rely on the 351(k) pathway, and shifts the balance between competition and the evidence historically used to support substitution decisions.
The change will affect manufacturers, payers, pharmacies, hospitals, and FDA implementation workstreams.
At a Glance
What It Does
The bill revises 42 U.S.C. 262(k) so that a biosimilar licensed under the 351(k) pathway is generally deemed interchangeable with its reference product either upon licensure or on a transition date 60 days after enactment. It preserves any unexpired ‘first interchangeable’ exclusivity for products licensed before enactment and removes several statutory references to an FDA interchangeability determination elsewhere in the U.S. code. It also mandates FDA guidance updates and targeted edits to pediatric‑assessment language in the FD&C Act.
Who It Affects
Biosimilar developers, originator biologic sponsors, pharmacists and state substitution regimes, payers and health systems, and the Food and Drug Administration. The change is most consequential for manufacturers that plan to commercialize biosimilars relying on a shared reference product and for entities that manage substitution and formularies.
Why It Matters
By eliminating the default need for a separate interchangeability determination, the bill lowers a regulatory barrier that has slowed substitution and competition. That can hasten price competition and increase pharmacy substitution, but it also upends the evidence expectations that supported automatic substitution and alters exclusivity incentives for originator and biosimilar sponsors.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites how interchangeability works under the biosimilar pathway. Rather than requiring a sponsor to submit separate switching studies or other interchangeability‑specific evidence and obtain an affirmative FDA interchangeability determination, the statute will treat biosimilars licensed under 351(k) as interchangeable by operation of law in most situations.
The core legal switch happens through two timing rules: products licensed on or after a 60‑day transition date are deemed interchangeable upon licensure unless they would conflict with an existing interchangeable exclusivity tied to another product; products licensed before the transition date become deemed interchangeable on that transition date, again subject to the exclusivity exception.
The exclusivity exception is narrowly framed: if an applicable biosimilar relies on the same reference product as a biological product that already had licensure in effect at enactment and that product still enjoys a first‑interchangeable exclusivity period, the new biosimilar cannot be deemed interchangeable until that exclusivity ends. At the same time, the bill expressly preserves any unexpired first‑interchangeable exclusivity periods for products licensed before enactment, so sponsors do not lose the remainder of those protections.Beyond the headline switch to automatic interchangeability, the bill makes several conforming edits across federal law to remove statutory language that presumes a distinct interchangeability finding, and it amends pediatric‑assessment language in the FD&C Act to clarify when a biosimilar should be treated as having a “new active ingredient” for pediatric study purposes.
Finally, the bill orders FDA to update, revise, or revoke existing interchangeability guidances (including the May 2019 and June 2024 documents named in the text) and to publish new or revised guidance documents on the biosimilarity evidence standard within an 18‑month clock, with subsequent follow‑up drafts or final versions after the comment period closes. Those guidance deadlines create a staged implementation path but leave operational details—labeling, state substitution rules, pharmacy workflow, and interchangeability notices—to agencies and downstream actors to sort out.
The Five Things You Need to Know
The bill deems a biosimilar licensed under 42 U.S.C. 262(k) to be ‘interchangeable’ by operation of law—either upon licensure (for products licensed on/after the transition date) or on the 60‑day transition date for products licensed earlier.
If an applicable biosimilar relies on the same reference product as an already‑licensed biological product that has a first‑interchangeable exclusivity period in force at enactment, the new biosimilar is not deemed interchangeable until that exclusivity expires.
Any unexpired period of first‑interchangeable exclusivity that existed for a biological product licensed before enactment is preserved for its remaining duration.
The bill removes statutory cross‑references to an affirmative interchangeability determination from other provisions, and it revises 505B(l) of the FD&C Act to change when a biosimilar counts as having a ‘new active ingredient’ for pediatric assessment purposes.
The FDA must update, revise, or revoke its existing interchangeability guidances (including the May 2019 and June 2024 documents named in the bill) and issue revised guidance on biosimilarity data requirements within 18 months of enactment, with follow‑up drafts or final versions after the comment period closes.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Declares the Act’s name as the “Biosimilar Red Tape Elimination Act.” This is purely a captioning clause with no substantive effect except to provide the bill’s identifiable title for citations and references.
Rewrites and reorganizes the biosimilar licensing subsection
The bill restructures subsection (k), removing the separate subsection heading that referenced interchangeability and cleaning up internal cross‑references. These textual edits are preparatory but important: they realign the statutory language so that ‘biosimilar’ licensing and interchangeability consequences are handled in the same part of the statute rather than as separate tracks. Practically, the reorganization simplifies the statute and reduces ambiguity about where interchangeability status is established.
Deemed interchangeability, transition date, and the exclusivity exception
This is the operative change: the bill adds a rule that a biosimilar licensed under subsection (k) is ‘deemed to be interchangeable’ subject to a narrowly defined timing exception. The transition date is 60 days after enactment. For products licensed on or after that transition date, interchangeability is effective on licensure unless the product relies on the same reference product as another biologic that, as of enactment, had licensure in effect and an active first‑interchangeable exclusivity period; in that case interchangeability attaches only when that exclusivity ends. For products licensed prior to the transition date, the effect is similar but the deemed interchangeability becomes effective on the transition date rather than on licensure. This scheme preserves temporal priority for a previously protected interchangeable product while otherwise sweeping in most biosimilars as interchangeable.
Keeps any unexpired first‑interchangeable exclusivity intact
For interchangeable biologics already licensed before enactment that had a remaining period of first‑interchangeable exclusivity, the bill leaves that unexpired exclusivity untouched. That clause prevents retroactive loss of exclusivity for products already on the market and preserves the remaining legal protection for their exclusivity window.
Removes interchangeability references across statutes and imposes guidance deadlines
The bill performs a set of conforming edits: it replaces language elsewhere (42 U.S.C. 262(i)(3), 42 U.S.C. 263–1, and 21 U.S.C. 379j–51(14)) that previously assumed an affirmative interchangeability finding. It also replaces subsection 505B(l) of the FD&C Act to clarify when a biosimilar counts as having a new active ingredient for pediatric assessment. Separately, the bill directs FDA to update or revoke specific interchangeability guidances (naming the May 2019 and June 2024 documents) and to issue revised guidance on the data an applicant must submit to show biosimilarity within an 18‑month period, and then finalize or reissue draft or final versions after the public comment period.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Biosimilar manufacturers: The bill removes the need for a separate interchangeability determination in many instances, lowering the regulatory barrier and shortening the path from licensure to pharmacy substitution—reducing development cost and time-to-market pressure. That boosts commercial prospects for companies that already relied on 351(k) for approval.
- Payers and purchasers (insurers, PBMs, government programs): Faster legal interchangeability increases the likelihood of therapeutic substitution at the pharmacy level and greater price competition, which can lower net spending on biologics.
- Pharmacies and integrated health systems: Clearer federal legal status for substitution reduces the regulatory ambiguity pharmacists face about dispensing biosimilars versus originator products, potentially simplifying formulary management and inventory decisions.
- Patients with chronic biologic needs: Increased competition and substitution can expand access and lower out‑of‑pocket costs where payers favor biosimilars, particularly for high‑cost biologic therapies.
Who Bears the Cost
- Originator biologic sponsors: Deemed interchangeability reduces the incentive value of seeking interchangeability exclusivity going forward and accelerates competitive substitution against reference products, eroding market share and pricing power except where pre‑existing exclusivity remains.
- FDA and its review divisions: The agency must rewrite, revoke, and reissue multiple guidances and rework internal review standards and templates within tight statutory deadlines, increasing workload and rule‑making risk.
- Clinicians and state pharmacy regulators: State substitution laws and professional practice rules will need reconciliation with the new federal default; pharmacies and prescribers face operational changes and potential liability or informed‑consent questions when substitution becomes more common.
- Patients and clinicians concerned with switching evidence: Because the bill effectively removes the need for interchangeability‑specific switching data in many cases, clinicians and patient advocacy groups may face reduced clinical evidence about repeated switching and immunogenicity for particular biosimilar/reference pairs, creating a potential safety‑information gap.
Key Issues
The Core Tension
The bill forces a classic trade‑off: accelerate biosimilar entry, substitution, and price competition by removing an FDA procedural barrier, versus preserve the additional clinical evidence and market incentives that a formal interchangeability finding has historically provided to support safe automatic substitution and to reward innovators. Speed and competition come at the cost of changing how comfort with switching is built and paid for.
The bill resolves a regulatory bottleneck by fiat—it does not require additional clinical switching studies to support deemed interchangeability. That raises a core implementation problem: pharmacy substitution decisions and state laws historically rely on an FDA interchangeability determination founded on specific switching evidence.
With the federal statute now creating legal interchangeability by default, states, professional boards, and insurers must decide whether to change their substitution policies, which could produce a patchwork of practices and operational friction.
There is also a tricky exclusivity calculus. The text preserves any unexpired ‘first interchangeable’ exclusivity for products already licensed, but it allows subsequent biosimilars to be deemed interchangeable once that exclusivity ends.
For products that share the same reference listing, the timing rules and the phraseology about “relying on the same reference” will require careful operational definitions and may spur litigation over whether a new product relies on the same reference or whether exclusivity attaches. Finally, the mandated guidance rewrites create a defined but not immediate timetable: 18 months is long enough to influence commercial plans and short enough to leave a protracted period of uncertainty about labels, interchangeability statements, and FDA review expectations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.